While the blast frequency of TET2-deficient CebpaΔ/p30 AML decreased upon 5-AZA treatment ( − 62%; Fig. 6b), the treatment did not significantly decrease the frequency of TET2-proficient cells. Here, TET2 is linked to acute myeloid leukemia.